Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel + Cadonilimab in advanced gastric cancer
NCT06349967Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2024
- Primary completion
- Apr 2027
- Modality
- Bispecific Antibodies
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in gastric cancer (GC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Objective Response Rate up to 24 months. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06349967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06349967.